SET/TAF-I antibody

Catalog No. ABIN4620361

Product Details anti-SET/TAF-I Antibody

Target: SET/TAF-I (SET) (SET Nuclear Oncogene (SET))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This SET/TAF-I antibody is un-conjugated

Application: Western Blotting (WB)

Specificity: This antibody detects I2PP2A / SET, widely expressed. Low levels in quiescent cells during serum starvation, contact inhibition or differentiation. Highly expressed in Wilms' tumor.

Purification: Affinity chromatography

Immunogen: Synthetic peptide derived from the human SET protein

Isotype: IgG

Application Details

Application Notes: Western blot (1: 400 dilution).
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Buffer: Phosphate buffered saline with 0.08 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: -20 °C

Storage Comment: Store the product (in aliquots) at -20 °C to -70 °C. Can be shipped at 2 - 8 °C.

References for anti-SET/TAF-I antibody (ABIN4620361)

Shih, Shih, Lee, Huang, Wang, Chen, Tsai: "Particle size distributions and health-related exposures of polychlorinated dibenzo-p-dioxins and dibenzofurans (PCDD/Fs) of sinter plant workers." in: Chemosphere, (2009) (PubMed).

Target Details for SET/TAF-I

Target: SET/TAF-I (SET) (SET Nuclear Oncogene (SET))

Alternative Name: SET / I2PP2A (SET Products)

Synonyms: 2PP2A antibody, I2PP2A antibody, IGAAD antibody, IPP2A2 antibody, PHAPII antibody, TAF-I antibody, TAF-IBETA antibody, 2610030F17Rik antibody, 5730420M11Rik antibody, AA407739 antibody, I-2PP2A antibody, StF-IT-1 antibody, 2pp2a antibody, i2pp2a antibody, igaad antibody, ipp2a2 antibody, phapii antibody, set antibody, set-a antibody, set-b antibody, taf-ibeta antibody, wu:fb30g11 antibody, wu:fd16c08 antibody, SET nuclear proto-oncogene antibody, SET nuclear oncogene antibody, SET translocation antibody, SET nuclear proto-oncogene L homeolog antibody, SET nuclear proto-oncogene b antibody, SET antibody, Set antibody, LOC403555 antibody, set.L antibody, setb antibody

Background: Human SET was originally identified as part of the SET-CAN fusion gene produced by a somatic translocation event in a patient with acute undifferentiated leukemia. In developing kidney, SET is highly expressed in the zone of nephron morphogenesis. SET has been shown to be a potent and specific inhibitor of protein phosphatase 2A, a family of major serine/threonine phosphatases involved in regulating cell proliferation and differentiation. SET is also involved in the regulation of renal cell proliferation and tumorigenesis. SET mRNA expression is markedly reduced in cells rendered quiescent by serum starvation, contact inhibition, or differentiation. SET protein expression is also much greater in developing rat and human kidney than in fully differentiated, mature kidney. High levels of SET mRNA and SET protein expression arefound in Wilms' tumor, but not in renal cell carcinoma, adult polycystic kidney disease or in transitional cell carcinoma.Synonyms: I-2PP2A, IGAAD, Inhibitor of granzyme A-activated DNase, PHAPII, Phosphatase 2A inhibitor I2PP2A, TAF-I, Template-activating factor I

Gene ID: 6418

NCBI Accession: NP_001116293

UniProt: H0UI37

Pathways: Apoptosis